From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in GI
Two clinical trials were conducted to assess the role of radiotherapy in the treatment of locally advanced rectal cancer. In the CONVERT trial, neoadjuvant chemotherapy (nCT) with CAPOX alone was
Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the
The LIBRETTO-531 study was specifically structured to explore the optimal primary treatment approach for individuals diagnosed with advanced medullary thyroid carcinoma (MTC). The study involved a meticulous comparison between selpercatinib
The KEYNOTE-585 and MATTERHORN studies delve into the role of adjuvant and neoadjuvant treatment involving checkpoint inhibitors in gastric cancer. Both trials randomise patients into groups undergoing chemotherapy before and
The advanTIG trial aimed to assess the impact of adding ociperlimab (OCI) to the standard care regimen of tislelizumab (TIS) + BAT1706 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma. The
In-depth stories about GI
As anticipated and subsequently confirmed, the CABINET study confirms that Vascular Endothelial Growth Factor (VEGF) inhibitors demonstrate efficacy not only in pancreatic Neuroendocrine Tumors (NETs) but also in extrapancreatic sites.
The CABATEN/GETNE-T1914 study constituted a comprehensive investigation across multiple cohorts to assess the synergistic impact of cabozantinib, a multi-kinase inhibitor, and atezolizumab, a PD-L1 inhibitor. The outcomes yielded results of
Professor Elleke Dresen of UZ Leuven (Belgium) delivered a presentation at ESMO 2023 focusing on the significance of radiological staging for colorectal cancers, particularly in identifying high-risk patients.
Historically,
Prof Hans Prenen, medical oncologist at UZA in Antwerp, delivered a lecture elucidating the pertinent biomarkers in metastatic colon cancer (mCRC). Unlike well-established subtypes in breast and lung cancers, classifying
The KEYNOTE-177 trial, renowned in the medical community, delves into the comparison between pembrolizumab and chemotherapy as the first-line treatment for patients with MSI-H/dMMR metastatic colorectal cancer (mCRC). Gastrointestinal oncologists
Professor Jeroen Dekervel from UZ Leuven (Leuven, Belgium) and Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center (New York, USA), both specialized in gastric oncology, discuss the interim analysis
In a discussion between prof Jeroen Dekervel from UZ Leuven and Dr Janjigian from Memorial Sloan Kettering Cancer Center in New York, both distinguished gastrointestinal oncologists, the focus centered on
In a thought-provoking conversation, Prof Jeroen Dekervel, a GI Oncologist at UZ Leuven, had the privilege of speaking with Dr. Kohei Shitara, a globally recognized expert in gastric cancer. Their
GI poster selection
Jonathan Decarpentrie, PhD researcher at the university of Namur presented his project focusing on the detection of epigenetic modifications of nucleosomes in glioblastoma by means of the Nu. Q® technology
Prof Marc van den Eynde, digestive oncologist at Cliniques Universitaires Saint-Luc in Brussels, presented the results of the AVETUXIRI phase II study with the combination of avelumab, cetuximab and irinotecan
Prof Jeroen Dekervel, gastrological oncologist at University Hospital Leuven and Dr Javier Carrasco, Grand Hospital de Charleroi, summarizes the poster presented.
R-IMMUNE: A phase Ib/II study to evaluate safety
Dr. Jules Colebunders and Dr. Vincent Liégeois, first-year residents at the University Hospital of Antwerp presented the research they performed during their master’s thesis. They did a retrospective analysis to
Prof Jong-Mu Sun, medical oncologist at Samsung Medical Center, Seoul, Republic of Korea presented the safety run-in results from the phase 3 LEAP-014 study, evaluating first-line lenvatinib plus pembrolizumab and
Dr Elena Benidovskaya, researcher at the Université Catholique de Louvain, Brussels presented their research on the microbiome in metastatic colorectal cancer. They explored and characterized the tissue-resident microbiota in the
Prof Maeve Lowery, consultant medical oncologist at St James’s hospital in Dublin, Ireland presents the health-related quality of life analysis from the KEYNOTE-859 trial, evaluating first-line pembrolizumab + chemotherapy for
With the educational support of: